Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBloomsbury Regulatory News (BMY)

Share Price Information for Bloomsbury (BMY)

Share Price is delayed by 15 minutes
Get Live Data
656.00    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 2.00 (0.304%)
Market Cap: £533.96m
BMY Live PriceLast checked at - London Stock Exchange

Intraday Bloomsbury Share Chart

Acquisition

6 Jan 2009 08:41

RNS Number : 1619L
Bloomsbury Publishing PLC
06 January 2009
 



 

Bloomsbury Publishing Plc

("Bloomsbury")

Bloomsbury acquires Arden Shakespeare

Bloomsbury Publishing Plc is pleased to announce the acquisition of Arden Shakespeare from Cengage Learning. This transaction is not material to Bloomsbury.

  Arden Shakespeare is the most academically rigorous Shakespeare series in print, and the best-known English literature brand worldwide. Originally created by the British publishing firm of Methuen in the late nineteenth century, and edited by a distinguished collection of scholars, the series took 25 years to complete from the launch of the first title, Edward Dowden's Hamlet, in 1899. In 1995 the Third Series of The Arden Shakespeare was launched. Now published under the imprint Arden Shakespeare, under the General Editorship of Richard Proudfoot, Ann Thompson, David Scott Kastan and Henry Woudhuysen, the Arden Shakespeare Third Series is nearing completion. Each new volume supersedes the corresponding Second Series text, being meticulously edited from the original sources by a contemporary scholar.

Arden Shakespeare will retain its internationally recognised name and become part of the Methuen Drama imprint (acquired in 2006 by A&C Black which is a wholly owned subsidiary of Bloomsbury). The acquisition will make Methuen Drama Europe's largest performing arts list, which includes work by Bertolt Brecht, Oscar Wilde, Bernard Shaw and Arthur Miller as well as contemporary playwrights such as Michael Frayn and Willy Russell, Methuen Student editions and the New Mermaids critical editions.

'I am delighted that the Arden Shakespeare series is returning to MethuenArden is a highly prestigious addition to our performing arts publishing and fits perfectly with our strategy of acquiring high quality perennial publishing lists which have significant potential for digital exploitation. We look forward to working with the Arden General Editors Richard Proudfoot, Ann Thompson, David Scott Kastan and Henry Woudhuysen to grow and strengthen this important list' says A&C Black Managing Director, Jill Coleman.

Jill Jones, CEO Cengage Learning EMEA said, 'The Arden Shakespeare is an excellent fit for Bloomsbury: we wish A&C Black, all volume editors, authors and General Editors from the Arden Shakespeare success for the future'.

www.methuendrama.com

-ends-

For further enquiries:

Bloomsbury Publishing PLC

Jill Coleman, Bloomsbury Publishing Plc care of Bell Pottinger

Bell Pottinger Corporate & Financial

Ben Woodford / Rosanne Perry +44 (0)20 7861 3232

Notes to Editors

About Bloomsbury Publishing Plc 

(www.bloomsbury.com and www.bloomsbury-ir.co.uk)

Bloomsbury Publishing is one of the world's leading independentpublicly quoted publishing houses with a reputation for a high quality management team and a highly valuable portfolio of intellectual properties including the Encarta World English Dictionary, JK Rowling's Harry Potter, Margaret Atwood, John Irving, David Guterson and Ben Schott. Other databases include Who's Who, Whitaker's AlmanackReed's Nautical Almanac, Black's Medical Dictionary, the Macmillan English Dictionary for Advanced Learners of EnglishBusiness: The Ultimate Resource and RSPB Handbook of British Birds. 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ACQUNOWRKKRARRR
Date   Source Headline
29th May 20082:52 pmRNSDirector/PDMR Shareholding
16th May 20087:00 amRNSInterim Management Statement
14th May 20089:06 amRNSDirector/PDMR Shareholding
25th Apr 20084:35 pmRNSDirector/PDMR Shareholding
24th Apr 20083:12 pmRNSDirector/PDMR Shareholding
10th Apr 20083:31 pmRNSHolding(s) in Company
1st Apr 20087:01 amRNSFinal Results
27th Mar 200810:40 amRNSDirector/PDMR Shareholding
11th Mar 200811:53 amRNSHolding(s) in Company
28th Feb 200812:06 pmRNSDirector/PDMR Shareholding
31st Jan 200810:22 amRNSDirector/PDMR Shareholding
22nd Jan 200811:20 amRNSAnnual Information Update
15th Jan 20087:01 amRNSTrading Statement
4th Jan 20085:06 pmRNSDealing by EBT
21st Dec 200711:30 amRNSDirector/PDMR Shareholding
19th Dec 200710:46 amRNSDirector/PDMR Shareholding
23rd Nov 20073:21 pmRNSDirector/PDMR Shareholding
19th Nov 20074:29 pmRNSBlocklisting Interim Review
11th Oct 200712:39 pmRNSHolding(s) in Company
9th Oct 20073:24 pmRNSHolding(s) in Company
8th Oct 20079:21 amRNSDirector/PDMR Shareholding
26th Sep 20074:43 pmRNSDirector appointment
26th Sep 20078:37 amRNSDirector/PDMR Shareholding
18th Sep 20077:02 amRNSInterim Results
10th Sep 20077:02 amRNSPublishing partnership
5th Sep 20072:08 pmRNSNotice of Results
5th Sep 20077:02 amRNSDirectorate Change
20th Aug 200711:50 amRNSHolding(s) in Company
13th Aug 20079:08 amRNSHolding(s) in Company
7th Aug 20079:58 amRNSHolding(s) in Company
3rd Aug 20072:30 pmRNSFinance Database Partnership
30th Jul 20077:01 amRNSDeathly Hallows
25th Jul 20075:14 pmRNSHolding(s) in Company
23rd Jul 20075:15 pmRNSFirst 24 hour sales
5th Jul 20075:51 pmRNSHolding(s) in Company
2nd Jul 20079:34 amRNSTotal Voting Rights
28th Jun 20071:28 pmRNSResult of AGM
28th Jun 20077:02 amRNSAGM Statement
18th Jun 20079:14 amRNSHolding(s) in Company
4th Jun 20075:08 pmRNSDirector/PDMR Shareholding
29th May 200710:39 amRNSNotice of AGM
18th May 200710:56 amRNSBlocklisting Interim Review
10th May 20075:26 pmRNSDirector/PDMR Shareholding
4th Apr 200711:52 amRNSDirector/PDMR Shareholding
3rd Apr 20077:02 amRNSFinal Results
30th Mar 200710:58 amRNSHolding(s) in Company
29th Mar 20078:54 amRNSHolding(s) in Company
9th Mar 200712:24 pmRNSHolding(s) in Company
6th Mar 20077:00 amRNSHolding(s) in Company
6th Mar 20077:00 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.